First Patient Gets Dose in Pfizer's Oral COVID-19 Drug Trial
"If successful, we believe this therapy could help reduce severity of illness among a broad population of patients," Rod MacKenzie, Pfizer's chief development officer, said in a statement.
The phase 2/3 study is analyzing a protease inhibitor currently known as PF-07321332. The drug is meant to combat COVID-19 in patients who experience symptoms from the disease but do not require hospital care.
The randomized, double-blind trial will enroll about 1,140 participants, approximately half of whom will receive a placebo. The participants will get the drug or the placebo every 12 hours orally for five days.
People who get the drug will also receive ritonavir.
“If successful, we believe this therapy could help reduce severity of illness among a broad population of patients,” Rod MacKenzie, Pfizer’s chief development officer, said in a statement.
The company already started a separate trial that’s testing a different protease inhibitor. That one is administered via IV.
Inhibitors are a type of medicine that stop viruses from replicating.
No antiviral pills against COVID-19 have yet been developed. The IV-administered remdesivir, produced by Gilead Sciences, was approved by U.S. drug regulators last year.
Other companies are also attempting to produce the medicines, including Merck and Roche.
Merck already started a late-stage trial analyzing its pill candidate, dubbed molnupiravir. Interim results from a phase 2 trial for Roche’s pill, AT-527, showed promising results, Roche and its partner Atea Pharmaceuticals said in July.
Pfizer has said that if its trial shows PF-07321332 is safe and effective, then it could ask regulators for authorization in the fourth quarter of this year.
By Zachary Stieber
Zachary Stieber covers U.S. news, including politics and court cases. He started at The Epoch Times as a New York City metro reporter.
The Epoch Times is the fastest-growing independent news media in America. We are nonpartisan and dedicated to truthful reporting.
We are free from the influence of any government, corporation, or political party—this is what makes us different from other media organizations. Our goal is to bring our readers accurate information so they can form their own opinions about the most significant topics of our time.
We don’t follow the unhealthy trend of agenda-driven journalism prevalent in today’s media environment. Instead, we use our principles of Truth and Tradition as our guiding light. We highlight in our reporting the best of humanity, the valuable lessons of history, and traditions that are beneficial for society.
The Epoch Times was founded in the United States in the year 2000 in response to communist repression and censorship in China. Our founders, Chinese-Americans who themselves had fled communism, sought to create an independent media to bring the world uncensored and truthful information.
The Epoch Times has received numerous awards for our reporting and design, including from the New York Press Association, the Society of Professional Journalists, and the Society for News Design.
The Epoch Times’ media network currently covers 21 languages and 33 countries.